JP2016212116A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016212116A5 JP2016212116A5 JP2016153332A JP2016153332A JP2016212116A5 JP 2016212116 A5 JP2016212116 A5 JP 2016212116A5 JP 2016153332 A JP2016153332 A JP 2016153332A JP 2016153332 A JP2016153332 A JP 2016153332A JP 2016212116 A5 JP2016212116 A5 JP 2016212116A5
- Authority
- JP
- Japan
- Prior art keywords
- prognosis
- survival
- diagnosis
- subject
- biomarkers
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 230000004083 survival Effects 0.000 claims 7
- 238000004393 prognosis Methods 0.000 claims 5
- 102100006044 MUC16 Human genes 0.000 claims 4
- 101700008449 MUC16 Proteins 0.000 claims 4
- 101700001465 NBR1 Proteins 0.000 claims 4
- 239000000090 biomarker Substances 0.000 claims 4
- 238000003745 diagnosis Methods 0.000 claims 4
- 102000004338 Transferrin Human genes 0.000 claims 2
- 108090000901 Transferrin Proteins 0.000 claims 2
- 238000010837 poor prognosis Methods 0.000 claims 2
- 239000012581 transferrin Substances 0.000 claims 2
- 101700077954 APOA1 Proteins 0.000 claims 1
- 102000005666 Apolipoprotein A-I Human genes 0.000 claims 1
- 108010059886 Apolipoprotein A-I Proteins 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 206010033128 Ovarian cancer Diseases 0.000 claims 1
- 102100009687 PPBP Human genes 0.000 claims 1
- 102000007584 Prealbumin Human genes 0.000 claims 1
- 108010071690 Prealbumin Proteins 0.000 claims 1
- 238000002512 chemotherapy Methods 0.000 claims 1
- 108010035886 connective tissue-activating peptide Proteins 0.000 claims 1
- 102000018511 hepcidin family Human genes 0.000 claims 1
- 108060003558 hepcidin family Proteins 0.000 claims 1
- 238000001356 surgical procedure Methods 0.000 claims 1
Claims (11)
- 卵巣癌を有するかまたは有する疑いのある対象の予後を判定する方法であって、バイオマーカー、トランスフェリンおよびβ-2ミクログロビンまたはApoA1およびCA125のレベルを比較する段階を含み、該バイオマーカーのレベルが参照基準に比して高いことによって予後不良が指し示される、前記方法。
- CA125、Apo-A1、トランスチレチン、トランスフェリン、ヘプシジン、CTAP3、およびβ-2ミクログロビンからなる群より選択される1つまたは複数の追加的なバイオマーカーのレベルを比較する段階をさらに含む、請求項1記載の方法。
- 対象試料におけるCA125のレベルを参照基準に存在するレベルと比較する段階をさらに含む、請求項1記載の方法。
- 初回手術の根治性、診断時の年齢、および治療のうち1つまたは複数を考慮する段階をさらに含む、請求項1記載の方法。
- FIGO病期、腫瘍の組織型、およびCA125のうち1つまたは複数を考慮する段階をさらに含む、請求項1記載の方法。
- 予後が全生存期間または無増悪生存期間の予測である、請求項1記載の方法。
- 1つまたは複数の前記バイオマーカーにおけるレベルの増大を検出できないことによって、良好な予後が指し示される、請求項1記載の方法。
- 対象の予後を治療レジメンの選択に用いる、請求項1記載の方法。
- 不良な予後は対象が積極的な治療レジメンを必要とすることを指し示し、かつ良好な予後は対象がより積極的でない治療レジメンを必要とすることを指し示す、請求項8記載の方法。
- 積極的な治療レジメンがネオアジュバント化学療法を含む、請求項9記載の方法。
- 全生存期間または無増悪生存期間が、診断後1〜2年間の生存；診断後2〜5年間の生存；および診断後5年超の生存からなる群より選択される、請求項6記載の方法。
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US40604410P | 2010-10-22 | 2010-10-22 | |
| US61/406,044 | 2010-10-22 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013535113A Division JP2013541716A (ja) | 2010-10-22 | 2011-10-21 | 卵巣癌の患者における予後予測バイオマーカー |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2016212116A JP2016212116A (ja) | 2016-12-15 |
| JP2016212116A5 true JP2016212116A5 (ja) | 2017-01-26 |
Family
ID=45975910
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013535113A Pending JP2013541716A (ja) | 2010-10-22 | 2011-10-21 | 卵巣癌の患者における予後予測バイオマーカー |
| JP2016153332A Pending JP2016212116A (ja) | 2010-10-22 | 2016-08-04 | 卵巣癌の患者における予後予測バイオマーカー |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013535113A Pending JP2013541716A (ja) | 2010-10-22 | 2011-10-21 | 卵巣癌の患者における予後予測バイオマーカー |
Country Status (5)
| Country | Link |
|---|---|
| EP (1) | EP2630498A4 (ja) |
| JP (2) | JP2013541716A (ja) |
| AU (1) | AU2011316844A1 (ja) |
| CA (1) | CA2818593A1 (ja) |
| WO (1) | WO2012054824A2 (ja) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3210220A1 (en) * | 2013-05-10 | 2014-11-13 | Johns Hopkins University | Compositions for ovarian cancer assessment having improved specificity |
| US10324084B2 (en) | 2014-04-23 | 2019-06-18 | Nichirei Biosciences Inc. | Combination product for detecting target marker |
| EP3435379A1 (en) * | 2017-07-27 | 2019-01-30 | Roche Diagnostics GmbH | Augmenting measurement values of biological samples |
| WO2019088709A2 (ko) * | 2017-10-31 | 2019-05-09 | 국립암센터 | Nc886 유전자를 이용한 난소암 예후 예측을 위한 정보제공방법 |
| JP7272627B2 (ja) * | 2019-01-24 | 2023-05-12 | 公立大学法人和歌山県立医科大学 | 卵巣腫瘍の評価用バイオマーカー |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1540010B8 (en) * | 2002-08-06 | 2010-07-14 | The Johns Hopkins University | Use of biomarkers for detecting ovarian cancer |
| WO2006019906A1 (en) * | 2004-07-14 | 2006-02-23 | The Regents Of The University Of California | Biomarker for early detection of ovarian cancer |
| AU2006223374B2 (en) * | 2005-03-11 | 2011-07-21 | Aspira Women’s Health Inc. | Biomarkers for ovarian cancer and endometrial cancer: hepcidin |
| US20100197561A1 (en) * | 2005-06-24 | 2010-08-05 | Ciphergen Biosystems, Inc. | Biomarkers for Ovarian Cancer: B2 Microglobulin |
| WO2008060376A2 (en) * | 2006-10-04 | 2008-05-22 | The Johns Hopkins University | Algorithims for multivariant models to combine a panel of biomarkers for assessing the risk of developing ovarian cancer |
| WO2008048508A2 (en) * | 2006-10-13 | 2008-04-24 | Vermillion, Inc. | Prognostic biomarkers in patients with ovarian cancer |
| JP2010532484A (ja) * | 2007-06-29 | 2010-10-07 | コレロジック システムズ，インコーポレイテッド | 卵巣癌のための予測マーカー |
| JP5391400B2 (ja) * | 2007-10-01 | 2014-01-15 | 公益財団法人ヒューマンサイエンス振興財団 | α−アクチニン−４遺伝子のコピー数または発現レベルを指標とした膵癌の検出を補助する方法および診断のためのキット |
| WO2009058331A2 (en) * | 2007-10-29 | 2009-05-07 | Vermilllion, Inc. | Biomarkers for the detection of early stage ovarian cancer |
| WO2010091763A1 (en) * | 2009-02-16 | 2010-08-19 | Atlas Antibodies Ab | Rbm3 as a marker for malignant melanoma prognosis |
-
2011
- 2011-10-21 CA CA2818593A patent/CA2818593A1/en not_active Abandoned
- 2011-10-21 AU AU2011316844A patent/AU2011316844A1/en not_active Abandoned
- 2011-10-21 WO PCT/US2011/057271 patent/WO2012054824A2/en active Application Filing
- 2011-10-21 EP EP11835211.1A patent/EP2630498A4/en not_active Ceased
- 2011-10-21 JP JP2013535113A patent/JP2013541716A/ja active Pending
-
2016
- 2016-08-04 JP JP2016153332A patent/JP2016212116A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016212116A5 (ja) | ||
| Feng et al. | Systemic immune-inflammation index (SII) is a useful prognostic indicator for patients with squamous cell carcinoma of the esophagus | |
| Iseki et al. | Impact of the preoperative controlling nutritional status (CONUT) score on the survival after curative surgery for colorectal cancer | |
| Hu et al. | The plasma lncRNA acting as fingerprint in non-small-cell lung cancer | |
| Shomali et al. | Can procalcitonin distinguish infectious fever from tumor‐related fever in non‐neutropenic cancer patients? | |
| Gertler et al. | Prevalence and topography of lymph node metastases in early esophageal and gastric cancer | |
| Liu et al. | Superior mesenteric artery margin of posttherapy pancreaticoduodenectomy and prognosis in patients with pancreatic ductal adenocarcinoma | |
| Varadhachary et al. | Carcinoma of unknown primary with gastrointestinal profile: immunohistochemistry and survival data for this favorable subset | |
| Wang et al. | Identification of serum monocyte chemoattractant protein-1 and prolactin as potential tumor markers in hepatocellular carcinoma | |
| La Torre et al. | Is a preoperative assessment of the early recurrence of pancreatic cancer possible after complete surgical resection? | |
| Ghanim et al. | Pretreatment serum C-reactive protein levels predict benefit from multimodality treatment including radical surgery in malignant pleural mesothelioma: a retrospective multicenter analysis | |
| Liu et al. | The RML of lymph node metastasis was superior to the LODDS for evaluating the prognosis of gastric cancer | |
| Ku et al. | Preoperative serum albumin as a prognostic factor in patients with upper urinary tract urothelial carcinoma | |
| Cashin et al. | Patient selection for cytoreductive surgery in colorectal peritoneal carcinomatosis using serum tumor markers: an observational cohort study | |
| Zhang et al. | Evaluation of preoperative hematologic markers as prognostic factors and establishment of novel risk stratification in resected pN0 non-small-cell lung cancer | |
| Chen et al. | A nomogram to predict prognostic value of red cell distribution width in patients with esophageal cancer | |
| Akagi et al. | Lymph node evaluation and survival in colorectal cancer: review of population-based, prospective studies | |
| Zhang et al. | The prognostic value of preoperative inflammation-based prognostic scores and nutritional status for overall survival in resected patients with nonmetastatic Siewert type II/III adenocarcinoma of esophagogastric junction | |
| Chu et al. | Impact on survival of the number of lymph nodes resected in patients with lymph node-negative gastric cancer | |
| Panotopoulos et al. | Elevated serum creatinine and low albumin are associated with poor outcomes in patients with liposarcoma | |
| Mafolasire et al. | Racial disparities in renal cell carcinoma: a single‐payer healthcare experience | |
| Riveiro‐Falkenbach et al. | DEK oncogene is overexpressed during melanoma progression | |
| Sejima et al. | Prognostic impact of preoperative hematological disorders and a risk stratification model in bladder cancer patients treated with radical cystectomy | |
| Lee et al. | Different lymph node staging systems in patients with gastric cancer from Korean: What is the best prognostic assessment tool? | |
| Vessies et al. | Combining variant detection and fragment length analysis improves detection of minimal residual disease in postsurgery circulating tumour DNA of stage II–IIIA NSCLC patients |